IsoRay Inc (ISR)
AMEX AMEX Primary Summary
Denison Mines: De-Risking And The New Phoenix ISR Milestone
Denison Mines Corp. (DNN) is rated BUY (conditional on CNSC license approval), with a $4.18 price target and 8% discount rate. The Phoenix ISR project positions DNN in the lowest global cost quartile, leveraging innovative freeze wall technology and strong internal funding. Securing grid power and advancing multiple projects, DNN is well-placed to benefit from surging uranium demand driven by AI data center growth.
Denison Mines' Phoenix ISR Project Ready for Construction Phase
DNN highlighted that its Phoenix ISR uranium project is construction-ready, awaiting final permits in early 2026, with first production targeted for mid-2028.
Huntington Ingalls Secures a $458M Deal to Modernize C5ISR Networks
HII wins a five-year contract worth $458 million from the U.S. DoD to modernize communications and information technology networks for the U.S. government.
IsoRay Inc (ISR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IsoRay Inc ever had a stock split?
IsoRay Inc Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Lori A. Holmes-Woods CEO | AMEX Exchange | 46489V104 CUSIP |
| US Country | 66 Employees | - Last Dividend | 17 Jun 2024 Last Split | - IPO Date |
Overview
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., is at the forefront of developing, manufacturing, and marketing isotope-based medical products and devices aimed at treating cancer and other malignant diseases. With a global reach, the company is dedicated to offering innovative treatments that target various types of cancers. Established in 1998 and headquartered in Richland, Washington, Isoray’s mission is to contribute significantly to the field of cancer treatment through its state-of-the-art products.
Products and Services
- CS-1 Cesium-131 brachytherapy seeds
The cornerstone of Isoray’s product line is the CS-1 Cesium-131 brachytherapy seed. Specifically designed for the effective treatment of various cancers, including those of the prostate, brain, lung, head and neck, as well as gynecological, pelvic/abdominal, and colorectal cancers, this product demonstrates Isoray’s commitment to providing versatile and efficient treatment options. The brachytherapy seeds work by delivering targeted radiation directly to the cancer cells, minimizing damage to surrounding healthy tissues and allowing for a more focused treatment approach.
